M6A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma

References

• Chen YP, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–21. doi:10.1016/S0140-6736(19)30956-0.
   PubMed Web of Science ®Google Scholar
• Luo W, Yao K, Busson P. Molecular characterization and clinical implications of spindle cells in nasopharyngeal carcinoma: a novel molecule-morphology model of tumor progression proposed. PloS One. 2013;8(12):e83135. doi:10.1371/journal.pone.0083135.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer Today. Lyon, France: International Agency for Research on Cancer; 2020. https://gco.iarc.fr/today.
   Google Scholar
• Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.31937.
   PubMed Web of Science ®Google Scholar
• Wei KR, Zheng R-S, Zhang S-W, Liang Z-H, Li Z-M, Chen W-Q. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):90. doi:10.1186/s40880-017-0257-9.
   PubMedGoogle Scholar
• Lam WKJ, Chan JYK. Recent advances in the management of nasopharyngeal carcinoma. F1000Res. 2018. 7:1829. doi:10.12688/f1000research.15066.1.
   Google Scholar
• Sun XS, Li X-Y, Chen Q-Y, Tang L-Q, Mai H-Q. Future of radiotherapy in nasopharyngeal carcinoma. Br J Radiol. 2019;92(1102):20190209. doi:10.1259/bjr.20190209.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L, Hu G-Q, Zhang N, Zhu X-D, Yang K-Y, Jin F, Shi M, Chen Y-P, Hu W-H, et al. Gemcitabine and Cisplatin Induction Chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019; 381(12):1124–1135. doi:10.1056/NEJMoa1905287.
   PubMed Web of Science ®Google Scholar
• Lee AWM, Ng WT, Chan JYW, Corry J, Mäkitie A, Mendenhall WM, Rinaldo A, Rodrigo JP, Saba NF, Strojan P, et al. Management of locally recurrent nasopharyngeal carcinoma. Cancer Treat Rev. 2019; 79:101890. doi:10.1016/j.ctrv.2019.101890.
   PubMed Web of Science ®Google Scholar
• Suárez C, Rodrigo JP, Rinaldo A, Langendijk JA, Shaha AR, Ferlito A. Current treatment options for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol. 2010;267(12):1811–1824. doi:10.1007/s00405-010-1385-x.
   PubMed Web of Science ®Google Scholar
• Lee HM, et al. 2019. Current perspectives on nasopharyngeal carcinoma. Adv Exp Med Biol. 1164:11–34.
   PubMed Web of Science ®Google Scholar
• Campion NJ, Ally M, Jank BJ, Ahmed J, Alusi G. The molecular march of primary and recurrent nasopharyngeal carcinoma. Oncogene. 2021;40(10):1757–1774. doi:10.1038/s41388-020-01631-2.
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962.
   PubMed Web of Science ®Google Scholar
• Ding C, Shan Z, Li M, Chen H, Li X, Jin Z. Characterization of the fatty acid metabolism in colorectal cancer to guide clinical therapy. Mol Ther Oncolytics. 2021. 20:532–544. doi:10.1016/j.omto.2021.02.010.
   PubMed Web of Science ®Google Scholar
• Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, Zhao F, You L, Zheng L, Zhang T, et al. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol. 2021; 14(1):14. doi:10.1186/s13045-020-01030-w.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Barker HE, Paget JTE, Khan AA, Harrington KJ. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat Rev Cancer. 2015;15(7):409–425. doi:10.1038/nrc3958.
   PubMed Web of Science ®Google Scholar
• Da Ros M, De Gregorio V, Iorio A, Giunti L, Guidi M, de Martino M, Genitori L, Sardi I. Glioblastoma Chemoresistance: the Double Play by microenvironment and blood-brain barrier. Int J Mol Sci. 2018;19(10):19(10. doi:10.3390/ijms19102879.
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018; 554(7693):538–543. doi:10.1038/nature25492.
   PubMed Web of Science ®Google Scholar
• Madden EC, Gorman AM, Logue SE, Samali A. Tumour cell secretome in chemoresistance and tumour recurrence. Trends Cancer. 2020;6(6):489–505. doi:10.1016/j.trecan.2020.02.020.
   PubMed Web of Science ®Google Scholar
• Ren B, Cui M, Yang G, Wang H, Feng M, You L, Zhao Y. Tumor microenvironment participates in metastasis of pancreatic cancer. Mol Cancer. 2018;17(1):108. doi:10.1186/s12943-018-0858-1.
   PubMed Web of Science ®Google Scholar
• Gong L, Kwong DLW, Dai W, Wu P, Wang Y, Lee AWM, Guan X-Y. The stromal and immune landscape of nasopharyngeal Carcinoma and its implications for precision medicine targeting the tumor microenvironment. Front Oncol. 2021. 11:744889. doi:10.3389/fonc.2021.744889.
   PubMed Web of Science ®Google Scholar
• Liu H, Tang L, Li Y, Xie W, Zhang L, Tang H, Xiao T, Yang H, Gu W, Wang H, et al. Nasopharyngeal carcinoma: current views on the tumor microenvironment’s impact on drug resistance and clinical outcomes. Mol Cancer. 2024; 23(1):20. doi:10.1186/s12943-023-01928-2.
   PubMed Web of Science ®Google Scholar
• Zhang L, Hou C, Chen C, Guo Y, Yuan W, Yin D, Liu J, Sun Z. The role of N(6)-methyladenosine (m(6)A) modification in the regulation of circRnas. Mol Cancer. 2020;19(1):105. doi:10.1186/s12943-020-01224-3.
   PubMed Web of Science ®Google Scholar
• Yang Y, Hsu PJ, Chen Y-S, Yang Y-G. Dynamic transcriptomic m(6)A decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28(6):616–624. doi:10.1038/s41422-018-0040-8.
   PubMed Web of Science ®Google Scholar
• Meyer KD, Jaffrey SR. The dynamic epitranscriptome: N6-methyladenosine and gene expression control. Nat Rev Mol Cell Biol. 2014;15(5):313–326. doi:10.1038/nrm3785.
   PubMed Web of Science ®Google Scholar
• Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, et al. RNA m 6 a methylation regulates sorafenib resistance in liver cancer through FOXO 3-mediated autophagy. EMBO J. 2020; 39(12):e103181. doi:10.15252/embj.2019103181.
   PubMed Web of Science ®Google Scholar
• Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, Yuan J, Rana TM. M 6 a RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. EMBO J. 2020;39(20):e104514. doi:10.15252/embj.2020104514.
   PubMed Web of Science ®Google Scholar
• Xu S, Tang L, Dai G, Luo C, Liu Z. Expression of m6A regulators correlated with immune microenvironment predicts therapeutic efficacy and prognosis in gliomas. Front Cell Dev Biol. 2020. 8:594112. doi:10.3389/fcell.2020.594112.
   PubMed Web of Science ®Google Scholar
• Li N, Kang Y, Wang L, Huff S, Tang R, Hui H, Agrawal K, Gonzalez GM, Wang Y, Patel SP, et al. ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment. Proc Natl Acad Sci U S A. 2020; 117(33):20159–20170. doi:10.1073/pnas.1918986117.
   PubMed Web of Science ®Google Scholar
• Zheng ZQ, Li Z-X, Zhou G-Q, Lin L, Zhang L-L, Lv J-W, Huang X-D, Liu R-Q, Chen F, He X-J, et al. Long noncoding RNA FAM225A promotes nasopharyngeal carcinoma tumorigenesis and metastasis by acting as ceRNA to sponge miR-590-3p/miR-1275 and upregulate ITGB3. Cancer Res. 2019; 79(18):4612–4626. doi:10.1158/0008-5472.CAN-19-0799.
   PubMed Web of Science ®Google Scholar
• Li ZX, Zheng Z-Q, Yang P-Y, Lin L, Zhou G-Q, Lv J-W, Zhang L-L, Chen F, Li Y-Q, Wu C-F, et al. WTAP-mediated m(6)A modification of lncRNA DIAPH1-AS1 enhances its stability to facilitate nasopharyngeal carcinoma growth and metastasis. Cell Death Differ. 2022; 29(6):1137–1151. doi:10.1038/s41418-021-00905-w.
   PubMed Web of Science ®Google Scholar
• Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNA modifications. Nat Rev Mol Cell Biol. 2017;18(1):31–42. doi:10.1038/nrm.2016.132.
   PubMed Web of Science ®Google Scholar
• Zhu H, Jia X, Wang Y, Song Z, Wang N, Yang Y, Shi X. M6A classification combined with tumor microenvironment immune characteristics analysis of bladder cancer. Front Oncol. 2021. 11:714267. doi:10.3389/fonc.2021.714267.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020;19(1):53. doi:10.1186/s12943-020-01170-0.
   PubMed Web of Science ®Google Scholar
• Li M, Zha X, Wang S. The role of N6-methyladenosine mRNA in the tumor microenvironment. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188522. doi:10.1016/j.bbcan.2021.188522.
   PubMed Web of Science ®Google Scholar
• Quan C, Belaydi O, Hu J, Li H, Yu A, Liu P, Yi Z, Qiu D, Ren W, Ma H, et al. N(6)-methyladenosine in cancer immunotherapy: an undervalued therapeutic target. Front Immunol. 2021; 12:697026. doi:10.3389/fimmu.2021.697026.
   PubMed Web of Science ®Google Scholar
• Zhang P, He Q, Lei Y, Li Y, Wen X, Hong M, Zhang J, Ren X, Wang Y, Yang X, et al. m(6)A-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression. Cell Death Disease. 2018; 9(12):1169. doi:10.1038/s41419-018-1224-3.
   PubMed Web of Science ®Google Scholar
• Meng QZ, Cong C-H, Li X-J, Zhu F, Zhao X, Chen F-W. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2. Eur Rev Med Pharmacol Sci. 2020;24(8):4328–4336. doi:10.26355/eurrev_202004_21014.
   PubMed Web of Science ®Google Scholar
• He JJ, Li Z, Rong Z-X, Gao J, Mu Y, Guan Y-D, Ren X-X, Zi Y-Y, Liu L-Y, Fan Q, et al. m(6)A Reader YTHDC2 promotes radiotherapy resistance of nasopharyngeal carcinoma via activating IGF1R/AKT/S6 signaling axis. Front Oncol. 2020; 10:1166. doi:10.3389/fonc.2020.01166.
   PubMed Web of Science ®Google Scholar
• Zhang L, MacIsaac KD, Zhou T, Huang P-Y, Xin C, Dobson JR, Yu K, Chiang DY, Fan Y, Pelletier M, et al. Genomic analysis of nasopharyngeal carcinoma reveals TME-Based subtypes. Mol Cancer Res. 2017; 15(12):1722–1732. doi:10.1158/1541-7786.MCR-17-0134.
   PubMed Web of Science ®Google Scholar
• Bao YN, Cao X, Luo D, Sun R, Peng L, Wang L, Yan Y, Zheng L, Xie P, Cao Y, et al. Urokinase-type plasminogen activator receptor signaling is critical in nasopharyngeal carcinoma cell growth and metastasis. Cell Cycle. 2014; 13(12):1958–1969. doi:10.4161/cc.28921.
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–1573. doi:10.1093/bioinformatics/btq170.
   PubMed Web of Science ®Google Scholar
• Spiwok V, Kříž P. Time-Lagged t-distributed stochastic neighbor embedding (t-SNE) of molecular simulation trajectories. Front Mol Biosci. 2020. 7:132. doi:10.3389/fmolb.2020.00132.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Brunet J-P, Tamayo P, Golub TR, Mesirov JP. Subclass mapping: identifying common subtypes in independent disease data sets. PloS One. 2007;2(11):e1195. doi:10.1371/journal.pone.0001195.
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14(1):7. doi:10.1186/1471-2105-14-7.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel III EE, Koeppen H, Astarita JL, Cubas R, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544–548. doi:10.1038/nature25501.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4(1):2612. doi:10.1038/ncomms3612.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545–15550. doi:10.1073/pnas.0506580102.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782–795. doi:10.1016/j.immuni.2013.10.003.
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, Li Z, Traugh N, Bu X, Li B, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550–1558. doi:10.1038/s41591-018-0136-1.
   PubMed Web of Science ®Google Scholar
• Lu X, Jiang L, Zhang L, Zhu Y, Hu W, Wang J, Ruan X, Xu Z, Meng X, Gao J, et al. Immune signature-based subtypes of cervical squamous cell carcinoma tightly associated with human papillomavirus type 16 expression. Molecul Featur Clin Outcome. Neoplasia. 2019; 21(6):591–601. doi:10.1016/j.neo.2019.04.003.
   Google Scholar
• Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi M, Bin J, Liao Y, Rao J, Liao W. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7(5):737–750. doi:10.1158/2326-6066.CIR-18-0436.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ma L, Goswami S, Ma J, Zheng B, Duan M, Liu L, Zhang L, Shi J, Dong L, et al. Landscape of infiltrating B cells and their clinical significance in human hepatocellular carcinoma. Oncoimmunology. 2019; 8(4):e1571388. doi:10.1080/2162402X.2019.1571388.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang T, Xiong H, Zeng L, Wang Z, Peng Y, Chen W, Hu X, Su T. Tumor-infiltrating CD4(+) central memory T cells correlated with favorable prognosis in oral squamous cell carcinoma. J Inflamm Res. 2022. 15:141–152. doi:10.2147/JIR.S343432.
   PubMed Web of Science ®Google Scholar
• Fiala GJ, Minguet S. Caveolin-1: the unnoticed player in TCR and BCR signaling. Adv Immunol. 2018;137:83–133.
   PubMed Web of Science ®Google Scholar
• Tanaka S, Baba Y. B Cell Receptor Signaling. Adv Exp Med Biol. 2020;1254:23–36.
   PubMed Web of Science ®Google Scholar
• Burger JA, Wiestner A. Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018;18(3):148–167. doi:10.1038/nrc.2017.121.
   PubMed Web of Science ®Google Scholar
• Courtney AH, Lo WL, Weiss A. TCR signaling: mechanisms of initiation and propagation. Trends Biochem Sci. 2018;43(2):108–123. doi:10.1016/j.tibs.2017.11.008.
   PubMed Web of Science ®Google Scholar
• Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27(1):591–619. doi:10.1146/annurev.immunol.021908.132706.
   PubMed Web of Science ®Google Scholar
• Li MO, Rudensky AY. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat Rev Immunol. 2016;16(4):220–233. doi:10.1038/nri.2016.26.
   PubMed Web of Science ®Google Scholar
• Wing JB, Tanaka A, Sakaguchi S. Human FOXP3(+) regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50(2):302–316. doi:10.1016/j.immuni.2019.01.020.
   PubMed Web of Science ®Google Scholar
• Zhou W, Guo S, Liu M, Burow ME, Wang G. Targeting CXCL12/CXCR4 axis in tumor immunotherapy. Curr Med Chem. 2019;26(17):3026–3041. doi:10.2174/0929867324666170830111531.
   PubMed Web of Science ®Google Scholar
• Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019;105(6):1319–1329. doi:10.1002/JLB.MR0718-269R.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang S, Li H, Wang H, Zhang T, Hutchinson MR, Yin H, Wang X. Small-molecule modulators of toll-like receptors. Acc Chem Res. 2020;53(5):1046–1055. doi:10.1021/acs.accounts.9b00631.
   PubMed Web of Science ®Google Scholar
• Wang S, He Z, Wang X, Li H, Liu X-S. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife. 2019. 8:8. doi:10.7554/eLife.49020.
   Web of Science ®Google Scholar
• Najafi M, Farhood B, Mortezaee K. Extracellular matrix (ECM) stiffness and degradation as cancer drivers. J Cell Biochem. 2019;120(3):2782–2790. doi:10.1002/jcb.27681.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang M, Xu F, Jiang S. Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities. Mol Cancer. 2020;19(1):165. doi:10.1186/s12943-020-01276-5.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1):165. doi:10.1186/s13045-020-00990-3.
   PubMed Web of Science ®Google Scholar
• Le PN, Keysar SB, Miller B, Eagles JR, Chimed T-S, Reisinger J, Gomez KE, Nieto C, Jackson BC, Somerset HL, et al. Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions. Mol Carcinog. 2019; 58(3):398–410. doi:10.1002/mc.22937.
   PubMed Web of Science ®Google Scholar
• Mosa MH, Michels BE, Menche C, Nicolas AM, Darvishi T, Greten FR, Farin HF. A Wnt-induced phenotypic switch in cancer-associated fibroblasts inhibits EMT in colorectal cancer. Cancer Res. 2020;80(24):5569–5582. doi:10.1158/0008-5472.CAN-20-0263.
   PubMed Web of Science ®Google Scholar
• Salaritabar A, Berindan-Neagoe I, Darvish B, Hadjiakhoondi F, Manayi A, Devi KP, Barreca D, Orhan IE, Süntar I, Farooqi AA, et al. Targeting hedgehog signaling pathway: paving the road for cancer therapy. Pharmacol Res. 2019; 141:466–480. doi:10.1016/j.phrs.2019.01.014.
   PubMed Web of Science ®Google Scholar
• Xin M, Ji X, De La Cruz LK, Thareja S, Wang B. Strategies to target the hedgehog signaling pathway for cancer therapy. Med Res Rev. 2018;38(3):870–913. doi:10.1002/med.21482.
   PubMed Web of Science ®Google Scholar
• Ma Z, Gao X, Shuai Y, Xing X, Ji J. The m6A epitranscriptome opens a new charter in immune system logic. Epigenetics. 2021;16(8):819–837. doi:10.1080/15592294.2020.1827722.
   PubMed Web of Science ®Google Scholar
• Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Liu Y, Wang J, Dougherty U, et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature. 2019; 566(7743):270–274. doi:10.1038/s41586-019-0916-x.
   PubMed Web of Science ®Google Scholar
• Gao Y, Vasic R, Song Y, Teng R, Liu C, Gbyli R, Biancon G, Nelakanti R, Lobben K, Kudo E, et al. m(6)A modification prevents formation of endogenous double-stranded RNAs and deleterious innate immune responses during hematopoietic development. Immunity. 2020; 52(6):1007–1021.e1008. doi:10.1016/j.immuni.2020.05.003.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J, Jiang Z, Zhang Y, Xu G, Zhang J, et al. METTL3-mediated m 6 a modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020; 69(7):1193–1205. doi:10.1136/gutjnl-2019-319639.
   PubMed Web of Science ®Google Scholar
• Netea MG, Joosten LAB, Latz E, Mills KHG, Natoli G, Stunnenberg HG, O’Neill LAJ, Xavier RJ. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. doi:10.1126/science.aaf1098.
   PubMed Web of Science ®Google Scholar
• Wu SY, Fu T, Jiang Y-Z, Shao Z-M. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120. doi:10.1186/s12943-020-01238-x.
   PubMed Web of Science ®Google Scholar
• Xie M, He J, He C, Wei S. γ secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer. J Cell Biochem. 2015;116(6):1019–1027. doi:10.1002/jcb.25056.
   PubMed Web of Science ®Google Scholar
• Lu H, Li Z-Y, Ding M, Liang C, Weng X-Q, Sheng Y, Wu J, Cai X. Trametinib enhances ATRA-induced differentiation in AML cells. Leuk Lymphoma. 2021;62(14):3361–3372. doi:10.1080/10428194.2021.1961231.
   PubMed Web of Science ®Google Scholar
• Ni X, Hu G, Cai X. The success and the challenge of all-trans retinoic acid in the treatment of cancer. Crit Rev Food Sci Nutr. 2019;59(sup1):S71–s80. doi:10.1080/10408398.2018.1509201.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu Q, Chen S, Liu Y, Huang Y, Chen P, Li X, Gao G, Xu K, Fan S, et al. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling. FASEB J. 2019; 33(11):11959–11972. doi:10.1096/fj.201802416RR.
   PubMed Web of Science ®Google Scholar
• Porta C, Tortora G, Larkin JM, Hutson TE. Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions. Future Oncol. 2016;12(4):533–549. doi:10.2217/fon.15.313.
   PubMed Web of Science ®Google Scholar
• Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11(6):694–703. doi:10.1634/theoncologist.11-6-694.
   PubMed Web of Science ®Google Scholar
• Ji X, Guo H, Tang Q, Ma D, Xue W. A targeted nanocarrier based on polyspermine for the effective delivery of methotrexate in nasopharyngeal carcinoma. Mater Sci Eng C Mater Biol Appl. 2017. 81:48–56. doi:10.1016/j.msec.2017.07.036.
   PubMed Web of Science ®Google Scholar